Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide monotherapy companion study after dexamethasone progression in relapsed/refractory multiple myeloma
NL-OMON39077Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Nov 2012
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Overall response rate. Started Nov 2012; status: active, not recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON39077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39077.